Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

myocardial cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adrenergic Receptor (9) Akt (4) AMPK (1) Angiotensin Receptor (2) Antibiotic (3) Apoptosis (13) Autophagy (2) Bacterial (2) Biochemical Assay Reagents (1) Calcium Channel (2) CXCR (3) Drug Metabolite (3) Endogenous Metabolite (1) Epigenetic Reader Domain (1) ERK (3) FGFR (1) HIF/HIF Prolyl-Hydroxylase (2) Integrin (6) Interleukin Related (1) MAP3K (1) MDM-2/p53 (2) Mitochondrial Metabolism (1) mTOR (2) Na+/H+ Exchanger (NHE) (1) NOD-like Receptor (NLR) (3) p38 MAPK (2) Prostaglandin Receptor (2) Protease Activated Receptor (PAR) (2) Pyroptosis (2) Reactive Oxygen Species (1) ROS Kinase (1) Serpin (1) Src (2) STAT (2) TRP Channel (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (44) Endocrinology (11) Infection (4) Inflammation/Immunology (13) Metabolic Disease (4) Neurological Disease (7)

By Targets:

Acyltransferase (1)

Adrenergic Receptor (9)

Akt (4)

AMPK (1)

Angiotensin Receptor (2)

Antibiotic (3)

Apoptosis (13)

Autophagy (2)

Bacterial (2)

Biochemical Assay Reagents (1)

Calcium Channel (2)

CXCR (3)

Drug Metabolite (3)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

ERK (3)

FGFR (1)

HIF/HIF Prolyl-Hydroxylase (2)

Integrin (6)

Interleukin Related (1)

MAP3K (1)

MDM-2/p53 (2)

Mitochondrial Metabolism (1)

mTOR (2)

Na+/H+ Exchanger (NHE) (1)

NOD-like Receptor (NLR) (3)

p38 MAPK (2)

Prostaglandin Receptor (2)

Protease Activated Receptor (PAR) (2)

Pyroptosis (2)

Reactive Oxygen Species (1)

ROS Kinase (1)

Serpin (1)

Src (2)

STAT (2)

TRP Channel (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (44)

Endocrinology (11)

Infection (4)

Inflammation/Immunology (13)

Metabolic Disease (4)

Neurological Disease (7)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99891

Rovelizumab	Integrin	Cardiovascular Disease
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .

HY-17369

Tirofiban hydrochloride monohydrate 1 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369B

Tirofiban 1 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-107335

Aplodan Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate	Biochemical Assay Reagents	Cardiovascular Disease
Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .

HY-121259

Doxorubicinol Adriamycinol; DXR-OL	Endogenous Metabolite	Cardiovascular Disease
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.

HY-116960

FR 76830	Others	Neurological Disease
FR 76830 is a bradycardic agent with myocardial cell protection .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-B1448A

Benidipine KW-3049 free base	Apoptosis Calcium Channel	Cardiovascular Disease
Benidipine is a potent and orally active calcium channel antagonist . Benidipine shows anti-apoptosis effects in ischaemic/reperfused myocardial cells . Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats .

HY-N7071

Maduramicin Maduramycin	Antibiotic Apoptosis	Infection
Maduramicin (Maduramycin) is isolated from the actinomycete Actinomadura rubra. Maduramicin is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection . Maduramicin induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways .

HY-125144

BIIB 513	Na+/H+ Exchanger (NHE)	Cardiovascular Disease
BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC₅₀ of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load .

HY-17369BR

Tirofiban (Standard)	Integrin	Cardiovascular Disease
Tirofiban (Standard) is the analytical standard of Tirofiban. This product is intended for research and analytical applications. Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369R

Tirofiban (hydrochloride monohydrate) (Standard)	Integrin	Cardiovascular Disease
Tirofiban (hydrochloride monohydrate) (Standard) is the analytical standard of Tirofiban (hydrochloride monohydrate). This product is intended for research and analytical applications. Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-N2190

Hederagenin 28-O-beta-D-glucopyranosyl ester	Others	Cardiovascular Disease Inflammation/Immunology
Hederagenin 28-O-beta-D-glucopyranosyl ester, a triterpenoid saponin isolated from Ilex cornuta, exhibits protective effects against H₂O₂-induced myocardial cell injury .

HY-N7071A

Maduramicin ammonium Maduramycin ammonium	Bacterial Apoptosis Antibiotic	Infection
Maduramicin ammonium (Maduramycin ammonium) is isolated from the actinomycete Actinomadura rubra. Maduramicin ammonium (Maduramycin ammonium) is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection . Maduramicin ammonium (Maduramycin ammonium) induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways .

HY-126852

4-Hydroxy Atorvastatin lactone P-Hydroxyatorvastatin lactone; 4-ATL	Drug Metabolite	Metabolic Disease Inflammation/Immunology
4-Hydroxy Atorvastatin lactone is a metabolite of Atorvastatin (HY-B0589). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids .

HY-B1448AS

(Rac)-Benidipine-d7	Apoptosis Calcium Channel	Cardiovascular Disease
(Rac)-Benidipine-d₇ is the deuterium labeled Benidipine[1]. Benidipine is a potent and orally active calcium channel antagonist[2]. Benidipine shows anti-apoptosis effects in ischaemic/reperfused myocardial cells[3]. Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats[4].

HY-130272

Anti-MI/R injury agent 1	Others	Cardiovascular Disease
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .

HY-N0107

Cyclovirobuxine D	Apoptosis Autophagy mTOR Akt	Cardiovascular Disease
Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-W835723

1-(2,6-Dimethoxyphenyl)-3-(4-hydroxyphenyl)propan-1-one	Others	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
1-(2,6-Dimethoxyphenyl)-3-(4-hydroxyphenyl)propan-1-one is a phenolic compound derived from Dracaena cochinchinensis that exhibits antioxidant, antimicrobial, antiviral, hemostatic, antithrombotic, anti-inflammatory activities, and protects myocardial cells .

HY-105218

Ifetroban BMS-180291	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-105218A

Ifetroban sodium 1 Publications Verification BMS-180291 sodium	Prostaglandin Receptor	Cardiovascular Disease Endocrinology Cancer
Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research .

HY-P4911

SDF-1α (human)	CXCR	Cardiovascular Disease
SDF-1α (human) is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) can be used in cardiovascular disease research .

HY-P4911A

SDF-1α (human) (TFA)	CXCR	Cardiovascular Disease
SDF-1α (human) TFA is a mononuclear cells chemoattractant that can bind to CXCR4. SDF-1α plays a central role in stem cell homing, retention, survival, proliferation, cardiomyocyte repair, angiogenesis and ventricular remodelling following myocardial infarction. SDF-1α (human) TFA can be used in cardiovascular disease research .

HY-110315

Ischemin sodium	Apoptosis MDM-2/p53 Epigenetic Reader Domain	Cardiovascular Disease
Ischemin sodium is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells. Ischemin sodium salt inhibits p53-induced p21 activation with an IC₅₀ value of 5 µM. Ischemin sodium salt also prevents apoptosis in ischemic cardiomyocytes. Ischemin sodium salt can be used in the study of cardiovascular diseases (such as myocardial ischemia) .

HY-N0202

Atractylenolide II 3 Publications Verification Asterolide	ERK Apoptosis p38 MAPK Akt Src STAT	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity .

HY-N7071AR

Maduramicin (ammonium) (Standard)	Bacterial Apoptosis Antibiotic	Infection
Maduramicin (ammonium) (Standard) is the analytical standard of Maduramicin (ammonium). This product is intended for research and analytical applications. Maduramicin ammonium (Maduramycin ammonium) is isolated from the actinomycete Actinomadura rubra. Maduramicin ammonium (Maduramycin ammonium) is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection . Maduramicin ammonium (Maduramycin ammonium) induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways .

HY-19867A

Burixafor hydrobromide 1 Publications Verification TG-0054 hydrobromide	CXCR	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent antagonist of CXCR4 and a well anti-angiogenic drug that is of potential value in treating choroid neovascularization . Burixafor hydrobromide (TG-0054 hydrobromide) mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction .

HY-N0107R

Cyclovirobuxine D (Standard)	Apoptosis Autophagy mTOR Akt	Cardiovascular Disease
Cyclovirobuxine D (Standard) is the analytical standard of Cyclovirobuxine D. This product is intended for research and analytical applications. Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .

HY-164304

INF 195	Pyroptosis Interleukin Related NOD-like Receptor (NLR)	Cardiovascular Disease Inflammation/Immunology
INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC₅₀ value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury .

HY-107571

VULM 1457	Acyltransferase	Cardiovascular Disease Metabolic Disease
VULM 1457 is a potent inhibitor of cholesterol acyltransferase (acyl-CoA). VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM 1457 has the potential for the research of diabetes mellitus and hypercholesterolaemia .

HY-N0202R

Atractylenolide II (Standard)	ERK Apoptosis p38 MAPK Src Akt STAT	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Atractylenolide II (Standard) is the analytical standard of Atractylenolide II. This product is intended for research and analytical applications. Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity .

HY-14994

SCH79797 dihydrochloride 2 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-14993

SCH79797 2 Publications Verification	Protease Activated Receptor (PAR) Apoptosis	Cardiovascular Disease
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC₅₀ of 70 nM and a K_i of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .

HY-134268

8-Br-7-CH-ADPR 8-Bromo-7-deazaadenosine-5'-O-diphosphoribose	TRP Channel	Cardiovascular Disease Neurological Disease Metabolic Disease
8-Br-7-CH-ADPR (8-Bromo-7-deazaadenosine-5'-O-diphosphoribose) is a specific TRPM2 antagonist that inhibits TRPM2 activation by binding to the NUDT9 homology domain of the TRPM2 channel, thereby controlling the influx of cations through the cell membrane channel. 8-Br-7-CH-ADPR can be used to study the role of TRPM2 in pathological processes such as cell death, neurodegenerative diseases, myocardial infarction, and diabetes .

HY-164853

Kanglexin	Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .

HY-W402074

5-Acetamide-Butenolide Butenolide	Mitochondrial Metabolism Reactive Oxygen Species	Metabolic Disease
5-Acetamide-Butenolide (Butenolide) is a mycotoxin with pro-oxidant activity, which is found in Fusarium. 5-Acetamide-Butenolide disrupts the mitochondrial membrane potential in primary neonatal rat cardiomyocytes. 5-Acetamide-Butenolide also induces the production of thiobarbituric acid reactive substances (TBARS) in isolated rat myocardial mitochondria. 5-Acetamide-Butenolide increases the production of reactive oxygen species (ROS), decreases the levels of GSH and reduces the viability of HepG2 cells .

HY-141510

myo-Inositol trispyrophosphate hexasodium ITPP hexasodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
myo-Inositol trispyrophosphate (ITPP) hexasodium is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate (ITPP) hexasodium is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate (ITPP) hexasodium enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate (ITPP) hexasodium can be used in the study of cardiovascular disease and cancer .

HY-121988

INF4E	NOD-like Receptor (NLR)	Inflammation/Immunology
INF4E is a potent NLRP3 inflammasome inhibitor. INF4E inhibits caspase-1 and NLRP3 ATPase activities. INF4E shows protection against the IR-induced myocardial injury and dysfunction .

HY-141510A

myo-Inositol trispyrophosphate hexa-triethylamine ITPP hexa-triethylamine	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
myo-Inositol trispyrophosphate (ITPP) hexa-triethylamine is a salt form of inositol triphosphate (ITPP). myo-Inositol trispyrophosphate hexa-triethylamine is a membrane-permeant hemoglobin allosteric regulator. myo-Inositol trispyrophosphate hexa-triethylamine enhances the oxygen release capacity of red blood cells by reducing the affinity of hemoglobin to oxygen. myo-Inositol trispyrophosphate hexa-triethylamine can be used in the study of cardiovascular disease and cancer .

HY-14299AR

Indacaterol (maleate) (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-14299R

Indacaterol (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-14299

Indacaterol 4 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .

HY-14299A

Indacaterol maleate 4 Publications Verification QAB149	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .

HY-14299D

Indacaterol acetate	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research .

HY-P10336

Serpinin	Serpin	Neurological Disease Endocrinology
Serpinin is an agonist of the protease inhibitor Nexin-1 (PN-1). Serpinin upregulates the expression of PN-1 through the cAMP-PKA-Sp1 signaling pathway, promoting granule biogenesis in endocrine cells. Serpinin is used in research related to the regulation of secretory function . Serpinin is a selective agonist for β-adrenergic receptors. Serpinin interacts with β1-adrenergic receptors to activate the AC-cAMP-PKA pathway, which regulates myocardial systolic and diastolic function. pGlu-serpinin upregulates Bcl2 mRNA transcription and exerts neuroprotective effects .

HY-12765

Losartan Carboxylic Acid E-3174; EXP-3174	Drug Metabolite Angiotensin Receptor	Cardiovascular Disease
Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The K_i values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure .

HY-12765R

Losartan Carboxylic Acid (Standard)	Drug Metabolite Angiotensin Receptor	Cardiovascular Disease
Losartan Carboxylic Acid (Standard) is the analytical standard of Losartan Carboxylic Acid. This product is intended for research and analytical applications. Losartan Carboxylic Acid (E-3174), an active carboxylic acid metabolite of Losartan, is an angiotensin II receptor type 1 (AT1) antagonist. The Ki values are 0.97, 0.57, 0.67 nM for rat AT1B/AT1A and human AT1, respectively. Losartan Carboxylic Acid blocks the angiotensin II-induced responses in vascular smoothmuscle cells (VSMC). Losartan Carboxylic Acid elevates plasma renin activities and reduces mean arterial pressure [4].

HY-B0076

Bisoprolol hemifumarate Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-129029

Bisoprolol Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-129029R

Bisoprolol (Standard)	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol (Standard) is the analytical standard of Bisoprolol. This product is intended for research and analytical applications. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

Cat. No.	Product Name	Target	Research Area